Stock VRTX VERTEX PHARMACEUTICALS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Vertex Pharmaceuticals Incorporated Stock

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-07 pm EDT 		5-day change 1st Jan Change
410.2 USD +1.92% Intraday chart for Vertex Pharmaceuticals Incorporated +4.44% +0.82%
May. 07 FOMO is Back Our Logo
May. 07 ANALYST RECOMMENDATIONS : Nvidia, The Home Depot, Lowe's, Rollins... Our Logo
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials (USD)

Sales 2024 * 10.75B Sales 2025 * 11.7B Capitalization 106B
Net income 2024 * 3.99B Net income 2025 * 4.44B EV / Sales 2024 * 8.53 x
Net cash position 2024 * 14.24B Net cash position 2025 * 19.45B EV / Sales 2025 * 7.39 x
P/E ratio 2024 *
26.8 x
P/E ratio 2025 *
24.1 x
Employees 5,400
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.95%
More Fundamentals * Assessed data

Chart Vertex Pharmaceuticals Incorporated

Dynamic Chart

Latest news about Vertex Pharmaceuticals Incorporated

FOMO is Back Our Logo
ANALYST RECOMMENDATIONS : Nvidia, The Home Depot, Lowe's, Rollins... Our Logo
Leerink Partners Adjusts Vertex Pharmaceuticals' Price Target to $529 From $511 MT
Stifel Adjusts Vertex Pharmaceuticals' Price Target to $420 From $430 MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $456 From $450, Keeps Overweight Rating MT
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $402 From $413, Keeps Equalweight Rating MT
RBC Adjusts Price Target on Vertex Pharmaceuticals to $424 From $417, Keeps Sector Perform Rating MT
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $577 From $574, Keeps Buy Rating MT
Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $458 From $450, Keeps Market Perform Rating MT
Vertex Pharmaceuticals Q1 Non-GAAP EPS, Revenue Increase MT
Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug DJ
Transcript : Vertex Pharmaceuticals Incorporated, Q1 2024 Earnings Call, May 06, 2024
Earnings Flash (VRTX) VERTEX PHARMACEUTICALS INCORPORATED Reports Q1 EPS $4.76, vs. Street Est of $4.06 MT
Vertex Pharmaceuticals Reiterates FY 2024 Total Product Revenue Guidance of $10.55-$10.75 Billion MT
Vertex Pharmaceuticals Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
More news

Latest transcript on Vertex Pharmaceuticals Incorporated

Logo Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, Q1 2024 Earnings Call, May 06, 2024
More transcripts

Analyst Recommendations on Vertex Pharmaceuticals Incorporated

ANALYST RECOMMENDATIONS : Nvidia, The Home Depot, Lowe's, Rollins... Our Logo
Leerink Partners Adjusts Vertex Pharmaceuticals' Price Target to $529 From $511 MT
Stifel Adjusts Vertex Pharmaceuticals' Price Target to $420 From $430 MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $456 From $450, Keeps Overweight Rating MT
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $402 From $413, Keeps Equalweight Rating MT
More recommendations

Press releases Vertex Pharmaceuticals Incorporated

Vertex: Q1 Earnings Snapshot AQ
Vertex Reports First Quarter 2024 Financial Results BU
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older BU
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES PR
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES AQ
More press releases

News in other languages on Vertex Pharmaceuticals Incorporated

EE.UU. - Valores a seguir en Wall Street (actualizado)
RECOMENDACIONES DE LOS ANALISTAS EE.UU./UK : Nvidia, The Home Depot, Palantir, Target, Lowe's, Block, Rollins...
Le marché ressuscite le Fed Put
Borsa di Italia: Il mercato resuscita la "Fed Put"
IN DIRETTA DAI MERCATI: Eni, Intesa Sanpaolo, Tenaris, Tod's, Davide Campari, Toscana Aeroporti, EQT, Berkshire Hathaway...
More news

Quotes and Performance

1 day+1.92%
1 week+4.44%
Current month+4.44%
1 month+0.88%
3 months-2.11%
6 months+8.46%
Current year+0.82%
More quotes

Highs and lows

1 week
394.03
Extreme 394.0323
415.67
1 month
391.01
Extreme 391.01
415.67
Current year
391.01
Extreme 391.01
448.40
1 year
320.01
Extreme 320.01
448.40
3 years
176.36
Extreme 176.36
448.40
5 years
164.07
Extreme 164.07
448.40
10 years
62.41
Extreme 62.405
448.40
More quotes

Managers and Directors - Vertex Pharmaceuticals Incorporated

Managers TitleAgeSince
Reshma Kewalramani CEO
 Chief Executive Officer 51 17-01-31
Jeffrey Leiden CHM
 Chairman 68 09-07-07
Charles Wagner DFI
 Director of Finance/CFO 55 19-04-09
Members of the board TitleAgeSince
Alan Garber BRD
 Director/Board Member 68 17-06-07
Jeffrey Leiden CHM
 Chairman 68 09-07-07
Bruce Sachs BRD
 Director/Board Member 64 97-12-31
More insiders

ETFs positioned on Vertex Pharmaceuticals Incorporated

Name Weight AuM 1st Jan change Investor Rating
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares -3x Short Biotechnology ETP Securities - USD
7.67% 0 M€ 0.00% -
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares 3x Long Biotechnology ETP Securities - USD
7.08% 0 M€ 0.00% -
More ETFs positioned on Vertex Pharmaceuticals Incorporated

Quotes

Date Price Change Volume
24-05-07 410.2 +1.92% 1,614,092
24-05-06 402.5 +0.35% 1,463,611
24-05-03 401.1 +0.23% 1,064,066
24-05-02 400.2 -0.49% 1,051,248
24-05-01 402.1 +2.38% 1,256,483

Delayed Quote Nasdaq, May 07, 2024 at 04:00 pm EDT

More quotes

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
Biotechnology & Medical Research
Calendar
2024-05-15 - Annual General Meeting
Related indices
S&P 500
More about the company

Income Statement Evolution

More financial data

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
410.2 USD
Average target price
461.7 USD
Spread / Average Target
+12.54%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+0.82% 106B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.44% 107B
ARGENX SE Stock argenx SE
+6.72% 23.47B
BIONTECH SE Stock BioNTech SE
-13.89% 21.9B
GENMAB A/S Stock Genmab A/S
-6.64% 18.77B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.26% 17.85B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.98% 16.78B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+8.67% 14.41B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+41.08% 12.86B
VIKING THERAPEUTICS, INC. Stock Viking Therapeutics, Inc.
+327.78% 8.78B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VRTX Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW